Table 2.

Inclusion and exclusion criteria

	Inclusion criteria	Exclusion criteria
Healthy volunteers	Written informed consent No contra-indication to MRI 40 years or above in age (attempts will be made to include similar age range as myeloma patients) No known significant illness No known metallic implant	Significant artefact on scan Corrupted scan data
Patients in phases 1 and 2	Patient with confirmed myeloma with WB-MRI scan previously performed as part of clinical care. Sufficient imaging and clinical data for the expert reference panel to categorise the WB-MRI scan as: Previously treated inactive disease with no evidence of active disease based on expert reference panel Active disease—focal Active disease—diffuse Active disease—extra-medullary New active myeloma, no previous treatment Patients may be included if the pattern of disease is a combination of focal, diffuse and/or extra-medullary.	Corrupted WB-MRI scan data. Insufficient clinical data to allow the expert reference panel to categorise the scan.
Patients in phase 3	Training set: phase 1 active disease cases and their post-treatment scans from phase 2. Validation set: from iTIMM study. Written informed consent for iTIMM study All patients over the age of 18 with multiple myeloma planned for autograft.	Corrupted scan data. MRI incompatible metal implants Claustrophobia Diagnosis of other malignancy within 5 years

iTIMM, Image-guided Theranostics in Multiple Myeloma; WB-MRI, Whole-Body Magnetic Resonance Imaging.